



About RERF

[Greetings](#)

[Objective and History](#)

[Organization](#)

[Operations and Finance/
Compliance with Laws](#)

[Yearly Schedule](#)

Research Activities

[Research Programs](#)

[Active Research Protocols](#)

[Radiation Health Effects](#)

[Highlights in Research Progress](#)

[Partner Graduate Schools](#)

Library

[Recent Scientific Papers](#)

[List of Publications](#)

[Downloadable Data](#)

[Historical Materials](#)

[Request for Publications](#)

Community Access

[Getting to RERF](#)

[Tour Reservations](#)

[Inquiries](#)

[Links](#)

[Site Map](#)

Search Site

[For further details](#)




[Top](#) > [RERF Glossary](#)

RERF Glossary

Following are terms, names, and abbreviations used frequently in the work of RERF scientists, as well as definitions of the major study populations being followed by RERF. Select a highlighted term to read its definition.

- A
 - [A-bomb Survivors Medical Treatment Law](#)
 - [Absolute risk](#)
 - [Adult Health Study \(AHS\)](#)
 - [ATB](#)
 - [Atomic Bomb Casualty Commission \(ABCC\)](#)
 - [Attributable risk](#)
- B
 - [Background radiation](#)
 - [Biological significance](#)
 - [Blue Ribbon Panel](#)
- C
 - [Chromosome mutation; balanced structural rearrangements](#)
 - [Commentary and Review Series \(CR\)](#)
 - [Confidence limits and confidence intervals \(error bars\)](#)
 - [Crow Committee](#)
- D
 - [Darling, George B.](#)
 - [Denaturing gradient gel electrophoresis \(DGGE\)](#)
 - [Deviance](#)
 - [Distally exposed](#)
 - [DNA fingerprint](#)
 - [Dose, organ](#)
 - [Dose response](#)
 - [Dose response, linear](#)
 - [Dose response, linear-quadratic](#)
 - [Dose, threshold](#)
 - [Dosimetry System 2002 \(DS02\)](#)
 - [Dosimetry System 1986 \(DS86\)](#)
- E
 - [Electron spin resonance \(ESR\) method](#)
 - [Epicenter](#)
 - [Epilation](#)
 - [Ethics Committee for Genome Research](#)
 - [Etiology](#)
 - [Excess relative risk](#)
 - [Excess risk](#)
- F
 - [First generation \(F₁\) born to atomic-bomb survivors](#)
 - [Fission products](#)
 - [Fluorescence *in situ* hybridization \(FISH\)](#)
 - [Francis Committee](#)
 - [Free-in-air kerma](#)
- G
 - [Germ-cell mutation](#)
 - [Giemsa-staining method](#)
 - [Gray \(Gy\)](#)
- H
 - [Honseki](#)
 - [Human genome at 4 levels of detail](#)
 - [Hypocenter](#)
- I
 - [Incidence](#)
 - [International Classification of Diseases \(ICD\)](#)



- [In utero study sample](#)
[Inversion \(chromosome mutation\)](#)
[Ionization](#)
- J** [Japanese Ministry of Health, Labour and Welfare \(MHLW\)](#)
[Japanese National Institute of Health \(JNIH\)](#)
- K** [Kerma](#)
- L** [Life Span Study \(LSS\)](#)
[Lifetime risk](#)
- M** [Marker gene](#)
[Master sample](#)
[Metaphase chromosome](#)
[Microsatellite](#)
[Minisatellite](#)
- N** [NIC](#)
[Ni-Hon-San cardiovascular study](#)
- P** [Pathogenesis](#)
[Pathology study](#)
[Petechia](#)
[Prevalence](#)
[Proximally exposed](#)
[Purpura](#)
- R** [Radiation, alpha](#)
[Radiation, beta](#)
[Radiation, gamma](#)
[Radiation, neutron](#)
[Radiation, X](#)
[Radon](#)
[Regression analysis](#)
[Relative biological effectiveness \(RBE\)](#)
[Relative risk](#)
[RERF Report \(RR\)](#)
[RERF Update](#)
[Research Protocols \(RP\)](#)
- S** [Sievert \(Sv\)](#)
[Significant radiation dose](#)
[Somatic mutation](#)
[Statistical significance](#)
- T** [Technical Report Series \(TR\)](#)
[Tentative 1965 dosimetry \(T65D\)](#)
[Translocation \(chromosome mutation\)](#)
[Tumor registries](#)
[Two-dimensional gel electrophoresis of DNA](#)
- U** [US Atomic Energy Commission \(AEC\)](#)
[US Department of Energy \(DOE\)](#)
[US National Academy of Sciences \(NAS\)-National Research Council \(NRC\)](#)